A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of transcranial direct current stimulation to the motor cortex after stroke (NETS): study protocol

被引:1
|
作者
The NETS Trial Collaboration Group
机构
[1] University Medical Center Hamburg-Eppendorf,Department of Neurology
[2] Medical University of South Carolina,Department of Health Sciences and Research, College of Health Professions
[3] KU Leuven,Department of Movement Sciences
[4] Swiss Federal Institute of Technology (EPFL),Defitech Chair of Clinical Neuroengineering, Centre for Neuroprosthetics (CNP) and Brain Mind Institute (BMI)
[5] Swiss Federal Institute of Technology Valais (EPFL Valais),Defitech Chair of Clinical Neuroengineering, CNP and BMI
[6] Clinic Romande de Readaptation (CRR),Clinical Neuroscience
[7] University Medical School of Geneva (HUG),Department of Medical Biometry and Epidemiology
[8] University Medical Center Hamburg-Eppendorf,undefined
来源
关键词
Brain stimulation; Clinical trial; Neuroplasticity; Neurorehabilitation; Recovery; Stroke; Therapy;
D O I
10.1186/s42466-022-00171-2
中图分类号
学科分类号
摘要
Introduction: The WHO estimates that each year 5 million people are left permanently disabled after stroke. Adjuvant treatments to promote the effects of rehabilitation are urgently needed. Cortical excitability and neuroplasticity can be enhanced by non-invasive brain stimulation but evidence from sufficiently powered, randomized controlled multi-center clinical trials is absent. Methods: Neuroregeneration enhanced by transcranial direct current stimulation (tDCS) in stroke (NETS) tested efficacy and safety of anodal tDCS to the primary motor cortex of the lesioned hemisphere in the subacute phase (day 5–45) after cerebral ischemia. Stimulation was combined with standardized rehabilitative training and repeatedly applied in 10 sessions over a period of 2 weeks in a planned sample of 120 patients. Primary outcome parameter was upper-extremity function at the end of the 2-weeks intervention period of active treatment or placebo (1:1 randomization), measured by the upper-extremity Fugl-Meyer assessment. Sustainability of the treatment effect was evaluated by additional follow-up visits after 30 and 90 days. Further secondary endpoints included metrics of arm and hand function, stroke impact scale, and the depression module of the patient health questionnaire. Perspective: NETS was aimed at providing evidence for an effective and safe adjuvant treatment for patients after stroke. Trial registration: ClinicalTrials.gov Identifier NCT00909714. Registered May 28, 2009. © 2022, The Author(s).
引用
收藏
相关论文
共 50 条
  • [21] Study protocol of a double-blind randomized control trial of transcranial direct current stimulation in post-stroke fatigue
    Tang, Wai Kwong
    Lu, Hanna
    Leung, Thomas Wai Hong
    Kim, Jong S.
    Fong, Kenneth Nai Kuen
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [22] Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial
    Sun, Yuanlong
    Hu, Na
    Chen, Gaofeng
    Wang, Yanjie
    Hu, Yiyang
    Ge, Maojun
    Zhao, Yu
    TRIALS, 2022, 23 (01)
  • [23] Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial
    Yuanlong Sun
    Na Hu
    Gaofeng Chen
    Yanjie Wang
    Yiyang Hu
    Maojun Ge
    Yu Zhao
    Trials, 23
  • [24] Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial
    Manuel Marquez-Romero, Juan
    Arauz, Antonio
    Luis Ruiz-Sandoval, Jose
    de la Cruz-Estrada, Erick
    Raquel Huerta-Franco, Maria
    Aguayo-Leytte, Geronimo
    Ruiz-Franco, Angelica
    Silos, Humberto
    TRIALS, 2013, 14
  • [25] Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial
    Juan Manuel Marquez-Romero
    Antonio Arauz
    José Luis Ruiz-Sandoval
    Erick de la Cruz-Estrada
    Maria Raquel Huerta-Franco
    Gerónimo Aguayo-Leytte
    Angélica Ruiz-Franco
    Humberto Silos
    Trials, 14
  • [26] Efficacy and safety of pentavalent rotavirus vaccine in Japan A randomized, double-blind, placebo-controlled, multicenter trial
    Iwata, Satoshi
    Nakata, Shuji
    Ukae, Susumu
    Koizumi, Yoshitugu
    Morita, Yasuyuki
    Kuroki, Haruo
    Tanaka, Yoshiyuki
    Shizuya, Toshiyuki
    Schoedel, Florian
    Brown, Michelle L.
    Lawrence, Jody
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (08) : 1626 - 1633
  • [27] Efficacy and Safety of Toutongning Capsule in Patients with Migraine: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Yu, Shengyuan
    Ran, Ye
    Wan, Qi
    Yang, Xiaosu
    Chen, Huisheng
    Wang, Hebo
    Hu, Xueqiang
    Mao, Shanping
    Yu, Tingming
    Luo, Guogang
    Guan, Yangtai
    Gao, Xuguang
    Li, Xin
    Zhou, Muke
    Li, Yu
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2019, 25 (12) : 1215 - 1224
  • [28] Percutaneous Bioelectric Current Stimulation in the Treatment of Chronic Achilles Tendinopathy: Protocol for a Double-Blind, Placebo-Controlled Randomized Multicenter Trial
    Schroeder, Philipp
    Molsberger, Albrecht
    Drabik, Attyla
    Karst, Matthias
    Merk, Harry
    JMIR RESEARCH PROTOCOLS, 2022, 11 (11):
  • [29] TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) OF THE PREFRONTAL CORTEX IN THERAPY-RESISTANT DEPRESSION: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Palm, U.
    Schiller, C.
    Fintescu, Z.
    Obermeier, M.
    Keeser, D.
    Reisinger, E.
    Pogarell, O.
    Nitsche, M.
    Moeller, H. -J.
    Padberg, F.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [30] Efficacy of Xinbao pill on chronic heart failure: Study protocol of a multicenter, randomized, double-blind, placebo-controlled trial
    Wang, Yuanping
    Li, Jiahua
    Yan, Jiaqi
    Wang, Yulin
    Cheng, Yuanyuan
    Liu, Zhongqiu
    Wang, Dawei
    FRONTIERS IN PHARMACOLOGY, 2022, 13